Abby Smith, 40, a NHS manager from Reading, has the rare autoimmune disease myasthenia gravis, which means she needs her ...

For this study, outcomes were compared between 2 groups of patients with myasthenia gravis: those who developed exacerbations ...

UCB, a global biopharmaceutical company, today announced the CHMP (Committee for Medicinal Products for Human Use) has issued a positive opinion for the self-administration of RYSTIGGO® ...

The FDA has granted priority review to a Biologics License Application for nipocalimab to treat individuals with generalized myasthenia gravis who ... of the treatment, diagnosis or prevention ...

Approval in Myasthenia gravis in key markets could eventually ... and continued to suffer from significant unresolved disease symptoms. These can include difficulties seeing, walking, talking ...

Several characteristic symptoms occur in individuals affected by myasthenia gravis. Get to know them now.

The Phase 1b/2a study will assess the safety of CNP-103 in adults (aged 18-35) and pediatrics (aged 12-17) who have Stage III or newly diagnosed (within the last 6 months) T1D as well as C-peptide ...

The UK regulatory authority has cleared the path for some patients with generalised myasthenia gravis (gMG ... struggle to manage the debilitating symptoms of this rare autoimmune disease." ...

Guillain-Barré Syndrome (GBS) poses a diagnostic challenge due to its misleading symptoms, the lack of a definitive test, and ...